Group 1 - The core viewpoint of the news highlights the strong performance of innovative drug ETFs in the Hong Kong market, driven by positive market sentiment and favorable industry trends [1][2][3] - The A-share market showed mixed results, with the Shanghai Composite Index up by 0.52% and the Shenzhen Component Index down by 0.06%, indicating a cautious trading environment [1] - The trading volume in the Shanghai and Shenzhen markets reached 1,102.2 billion yuan, a decrease of 43.6 billion yuan compared to the previous day, reflecting reduced investor activity [1] Group 2 - The Hong Kong innovative drug ETF (520880) led the gains with a rise of 6.00%, while the Hong Kong medical ETF (159366) and the Hang Seng Medical ETF (159557) also saw significant increases of 3.85% and 3.01%, respectively [2] - According to Zhongtai Securities, the innovative drug sector remains a clear investment theme with substantial growth potential, suggesting investors should actively embrace this sector [2] - The recent announcement of the 11th batch of drug procurement by the National Organization for Drug Procurement Office emphasizes a trend towards encouraging innovation, with new selection rules favoring innovative drugs [3]